Breaking News Instant updates and real-time market news.

WVE

Wave Life Sciences

$24.32

-9.73 (-28.58%)

, BMRN

BioMarin

$91.00

-0.86 (-0.94%)

11:16
04/16/19
04/16
11:16
04/16/19
11:16

Wave drug looks too much like failed BioMarin drug, Feuerstein says

STAT's Adam Feuerstein tweeted, "$WVE down on concerns that chosen doses for suvodirsen in DMD are too low to show efficacy. (And that higher doses not possible due to toxicity.) In short, suvodirsen looks too much like drisapersen, which you'll recall, failed in DMD." Wave Life Sciences shares are down 28%, or $9.52, to $24.50 in late morning trading.

WVE

Wave Life Sciences

$24.32

-9.73 (-28.58%)

BMRN

BioMarin

$91.00

-0.86 (-0.94%)

  • 16

    Apr

  • 16

    Apr

  • 16

    Apr

  • 25

    Apr

WVE Wave Life Sciences
$24.32

-9.73 (-28.58%)

11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/06/18
12/06/18
NO CHANGE

Mizuho defending Wave Life Sciences after stock decline
Mizuho analyst Salim Syed maintained a Buy rating and $65 price target on Wave Life Sciences, and defended the stock after its double digit decline. Syed said some of the decline was related to the broader market decline, as the tape is generally red, but some is Wave Life specific, as a lack of details in the company's recent press release has disappointed some investors. The analyst said he spoke to management and believes the decline is unwarranted, as management alleviated concerns regarding the drug trial.
04/16/19
LEER
04/16/19
NO CHANGE
LEER
Outperform
Wave Life Sciences suvodirsen data with little read-through for efficacy, says SVB Leerink
SVB Leerink analyst Mani Foroohar says that Wave Life Sciences' first-in-human safety data from the Phase I trial of suvodirsen in exon 51 skipping-amenable Duchenne Muscular Dystrophy shows that it was generally sage and well-tolerated up to the 5mg/kg dose, and notes the company has selected the 3.0mg/kg and 4.5mg/kg doses to pivotal trials. While the stock is trading down and investors seem to see negative read-throughs for the potential efficacy of suvodirsen at 5mg/kg, given that drisapersen was dosed at 6mg/kg in clinical trials, the analyst believes that due to differences in chemistry between the compounds, comparison of doses between drugs is not appropriate proxy of potential efficacy. Foroohar maintains his 30% probability of success on the suvodirsen program and reiterates an Outperform rating on the shares.
04/16/19
MZHO
04/16/19
NO CHANGE
Target $65
MZHO
Buy
Safety data from Wave Life's Exon-51 SAD DMD trial seems reasonably clean, says Mizuho
Mizuho analyst Salim Syed notes that Wave Life Sciences disclosed safety data from its Phase 1 Exon-51 SAD DMD trial, and based on this Phase 1 trial and preclinical work, the company has selected two doses to move forward into its Phase 2/3 trial, 3mg/kg and 4.5mg/kg. The analyst believes the safety data seems "reasonably clean," and that the Street should be not be getting hung up on the reported adverse events. Syed reiterates a Buy rating and $65 price target on the shares.
BMRN BioMarin
$91.00

-0.86 (-0.94%)

02/25/19
RHCO
02/25/19
NO CHANGE
Target $117
RHCO
Buy
BioMarin price target lowered to $117 from $126 at SunTrust
SunTrust analyst Edward Nash lowered his price target on BioMarin to $117 after its "tough Q4 and less inspiring 2019 guidance", saying all of the company's products except for Palynziq performed worse than expected. The analyst cites Latin America seasonal ordering patterns among the likely culprits, adding that the next potential catalyst for BioMarin - the June release of Phase I/II Study of Valrox - could also see a "downward trend of Factor VIII activity levels." Nash keeps his Buy rating on the shares longer term, stating that BioMarin's R&D competencies and a "strong sales force in Orphan markets will continue to provide strong revenue growth and durable barriers to entry".
02/25/19
FBCO
02/25/19
NO CHANGE
Target $47
FBCO
Neutral
Roche may spark another bull run for gene therapy names, says Credit Suisse
Credit Suisse analyst Martin Auster notes that the Wall Street Journal recently reported that Roche (RHHBY) is nearing a deal with Spark Therapeutics (ONCE) for $5B. The analyst believes the transaction value implies the re-emergence of Spark's hemophilia A gene therapy program with a competitive profile and substantial value assigned to additional pipeline programs, such as SPK-3006 for Pompe, and the technology platform. Spark's acquisition would further strengthen the company's position in the hemophilia space, he contends. Further, Auster argues that the deal may increase M&A interest among other gene therapy names in his coverage universe, which include BioMarin (BMRN), Sarepta (SRPT), Ultragenyx (RARE), PTC (PTC) and Solid Biosciences (SLDB). He sees particularly strong read-through to Sarepta. The analyst reiterates a Neutral rating and a $47 price target on Spark's shares.
03/04/19
CANT
03/04/19
NO CHANGE
Target $131
CANT
Overweight
BioMarin price target raised to $131 from $126 at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle raised her price target for BioMarin Pharmaceutical to $131 to reflect Friday's positive Committee for Medicinal Products for Human Use opinion on Palynziq. The analyst thinks the approval is supportive of base business revenue growth, and she models worldwide Palynziq sales of $900M. She keeps an Overweight rating on BioMarin.
04/09/19
RAJA
04/09/19
INITIATION
RAJA
Outperform
BioMarin resumed with an Outperform at Raymond James
Raymond James analyst Reni Benjamin resumed coverage on BioMarin with an Outperform and $110 price target. The analyst said baseline ultra-orphan business is on tract to generate $2.1B by 2024, key read-outs are expected in mid-2019 for its leading Hemophilia A gene therapy asset, and the current pipeline of seven revenue generating products, which could become nine by 2020, are modeled to generate $3.3B in sales by 2024.

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$71.10

1.69 (2.43%)

21:00
04/25/19
04/25
21:00
04/25/19
21:00
Recommendations
Seattle Genetics analyst commentary at Piper Jaffray »

Seattle Genetics Q1 marks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

  • 31

    May

  • 06

    Jun

TCBK

TriCo Bancshares

$39.57

-0.47 (-1.17%)

20:35
04/25/19
04/25
20:35
04/25/19
20:35
Earnings
TriCo Bancshares reports Q1 EPS 74c, consensus 71c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

XOM

Exxon Mobil

$82.25

0.51 (0.62%)

, CVX

Chevron

$117.93

-0.38 (-0.32%)

20:25
04/25/19
04/25
20:25
04/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

XOM

Exxon Mobil

$82.25

0.51 (0.62%)

CVX

Chevron

$117.93

-0.38 (-0.32%)

CL

Colgate-Palmolive

$68.64

-0.2 (-0.29%)

ADM

Archer Daniels

$41.77

-0.99 (-2.32%)

WY

Weyerhaeuser

$26.27

-0.07 (-0.27%)

AAL

American Airlines

$33.36

-0.64 (-1.88%)

LEA

Lear

$146.64

-6.455 (-4.22%)

IPG

Interpublic Group

$22.28

-0.26 (-1.15%)

GT

Goodyear Tire

$19.56

-0.54 (-2.69%)

AN

AutoNation

$39.43

0.91 (2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 30

    Apr

  • 01

    May

  • 08

    May

  • 10

    May

  • 16

    May

  • 17

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 04

    Jun

  • 12

    Jun

  • 13

    Nov

ATRC

AtriCure

$28.19

0.21 (0.75%)

20:18
04/25/19
04/25
20:18
04/25/19
20:18
Recommendations
AtriCure analyst commentary at Piper Jaffray »

AtriCure growth story…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 22

    May

NOW

ServiceNow

$260.95

18.54 (7.65%)

19:43
04/25/19
04/25
19:43
04/25/19
19:43
Recommendations
ServiceNow analyst commentary at Jefferies »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

GFI

Gold Fields

$3.74

0.08 (2.19%)

19:34
04/25/19
04/25
19:34
04/25/19
19:34
Upgrade
Gold Fields rating change at BMO Capital »

Gold Fields upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

19:28
04/25/19
04/25
19:28
04/25/19
19:28
Hot Stocks
Watchdog finds at least 78,000 reviews removed from Amazon »

Watchdog Which? said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

EHTH

eHealth

$62.23

0.32 (0.52%)

, MAT

Mattel

$12.30

-0.25 (-1.99%)

19:02
04/25/19
04/25
19:02
04/25/19
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

EHTH

eHealth

$62.23

0.32 (0.52%)

MAT

Mattel

$12.30

-0.25 (-1.99%)

KNL

Knoll

$20.57

-0.22 (-1.06%)

GRUB

GrubHub

$69.83

0.53 (0.76%)

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

F

Ford

$9.41

-0.17 (-1.77%)

COF

Capital One

$88.09

0.3 (0.34%)

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

COLM

Columbia Sportswear

$104.45

-0.65 (-0.62%)

SWN

Southwestern Energy

$4.03

-0.13 (-3.13%)

DFS

Discover

$77.48

0.43 (0.56%)

LOGM

LogMeln

$84.32

0.085 (0.10%)

BABY

Natus Medical

$25.20

0.54 (2.19%)

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

TMUS

T-Mobile

$72.68

-0.67 (-0.91%)

SBUX

Starbucks

$77.07

0.65 (0.85%)

ATEN

A10 Networks

$7.28

0.14 (1.96%)

PFPT

Proofpoint

$131.35

3.56 (2.79%)

FII

Federated Investors

$33.57

0.605 (1.84%)

INTC

Intel

$57.59

-1.13 (-1.92%)

BEAT

BioTelemetry

$59.26

0.52 (0.89%)

BGG

Briggs & Stratton

$13.61

-0.44 (-3.13%)

SKYW

SkyWest

$58.44

-1.31 (-2.19%)

SGEN

Seattle Genetics

$71.10

1.69 (2.43%)

VCRA

Vocera

$31.31

0.36 (1.16%)

ILMN

Illumina

$318.91

4.47 (1.42%)

INT

World Fuel Services

$31.15

0.1 (0.32%)

BMRN

BioMarin

$85.40

-0.06 (-0.07%)

MHK

Mohawk

$130.69

-3.46 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 28

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 24

    Jul

  • 06

    Aug

  • 03

    Sep

  • 23

    Oct

  • 13

    Nov

ATEN

A10 Networks

$7.28

0.14 (1.96%)

19:00
04/25/19
04/25
19:00
04/25/19
19:00
Earnings
A10 Networks sees Q2 EPS (8c) to 0c, two estimates 0c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ATEN

A10 Networks

$7.28

0.14 (1.96%)

18:59
04/25/19
04/25
18:59
04/25/19
18:59
Earnings
A10 Networks reports Q1 EPS (9c), two estimates (7c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CNC

Centene

$50.20

0.04 (0.08%)

18:44
04/25/19
04/25
18:44
04/25/19
18:44
Hot Stocks
Centene CEO: Most people are happy with their healthcare »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 29

    May

  • 23

    Jul

APHA

Aphria

$7.64

-0.17 (-2.18%)

18:23
04/25/19
04/25
18:23
04/25/19
18:23
Hot Stocks
Green Growth Brands says offer for Aphria has expired »

Green Growth Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$296.77

-0.35 (-0.12%)

18:21
04/25/19
04/25
18:21
04/25/19
18:21
Hot Stocks
Align Technology CEO: We are enjoying good growth in North America »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 05

    Jun

AAPL

Apple

$205.28

-1.82 (-0.88%)

18:21
04/25/19
04/25
18:21
04/25/19
18:21
Periodicals
Several veterans leave Apple's design team, WSJ reports »

Apple's design team…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

FB

Facebook

$193.23

10.59 (5.80%)

18:18
04/25/19
04/25
18:18
04/25/19
18:18
Hot Stocks
Canadian agency says probe shows Facebook broke privacy law »

Canada's Office of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

NOV

National Oilwell

$26.44

-0.04 (-0.15%)

18:17
04/25/19
04/25
18:17
04/25/19
18:17
Earnings
National Oilwell reports Q1 EPS (20c), consensus (8c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    May

  • 22

    May

  • 13

    Nov

FB

Facebook

$193.23

10.59 (5.80%)

18:16
04/25/19
04/25
18:16
04/25/19
18:16
Hot Stocks
Ireland's DPC opens statutory inquiry into Facebook »

Ireland's Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

FB

Facebook

$193.23

10.59 (5.80%)

18:15
04/25/19
04/25
18:15
04/25/19
18:15
Hot Stocks
NY AG to investigate Facebook's collection of user email contact databases »

New York State Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

18:09
04/25/19
04/25
18:09
04/25/19
18:09
Hot Stocks
Amazon.com says had 'a lot of good customer wins' in Q1 »

Says: Usage growth higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

FIBK

First Interstate

$41.94

-0.63 (-1.48%)

18:08
04/25/19
04/25
18:08
04/25/19
18:08
Earnings
First Interstate reports Q1 EPS 69c, consensus 72c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

F

Ford

$9.41

-0.17 (-1.77%)

18:03
04/25/19
04/25
18:03
04/25/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says improving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

PUB

People's Utah Bancorp

$28.02

0.09 (0.32%)

18:01
04/25/19
04/25
18:01
04/25/19
18:01
Earnings
People's Utah Bancorp reports Q1 EPS ,55c consensus 55c »

Reports Q1 NII $26.91M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 14

    May

  • 15

    May

AEGN

Aegion

$19.44

-0.58 (-2.90%)

17:57
04/25/19
04/25
17:57
04/25/19
17:57
Hot Stocks
Aegion subsidiary awarded three contracts valued at $13M total »

Aegion announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

17:55
04/25/19
04/25
17:55
04/25/19
17:55
Hot Stocks
Amazon.com says will spend $800M in Q2 to move to one-day Prime delivery »

Says: Need to build out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

F

Ford

$9.41

-0.17 (-1.77%)

17:53
04/25/19
04/25
17:53
04/25/19
17:53
Hot Stocks
Ford CFO: Encouraged by progress made in China toward return to profitability »

Sees FY19 revenue growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.